Drug intelligence / Profile preview

KR-335

Development stage: Preclinical
Lead developer: Kernal Biologics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
Administration: Intravenous

Overview

KR-335 is an investigational mRNA-based immunotherapeutic developed by Kernal Biologics for the treatment of cancer, including solid tumors such as triple-negative breast cancer. It utilizes Kernal Bio’s proprietary mRNA 2.0 platform to engineer selective mRNA-lipid nanoparticle (LNP) complexes that are designed to be selectively translated into therapeutic proteins within the tumor microenvironment. This approach aims to maximize anti-tumor efficacy while minimizing off-target effects and toxicity. Preclinical studies have demonstrated a high therapeutic index (100x), strong efficacy in solid tumors resistant to conventional immuno-oncology agents, and favorable tolerability in animal models[1][6]. The mechanism of action is described as protein synthesis stimulation within targeted cancer cells.

Other names: KR 335KR335KR-335

Targets

80S ribosome (Ribosome and ribosomal components)

Beyond the preview

Go deeper on KR-335.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR-335.

Explore the full profile